WeightWatchers slashes debt and rides GLP-1 wave to regain market dominance

WeightWatchers has cut its legacy debt by more than 70% after exiting Chapter 11 protection. The company's financial turnaround comes alongside a major shift in its business model, driven by the rise of GLP-1 medications in weight management. Recent results show strong growth in clinical services, helping it regain market share from competitors like Noom and Oria.

The company emerged from bankruptcy with a much lighter debt load, setting the stage for its new strategy. By 2025, WeightWatchers had introduced GLP-1-based clinical programmes, capitalising on its well-known brand and subscription model. This move boosted its market share in the weight management sector to 28% by Q1 2026—up 15 percentage points—while Noom's share fell to 22% due to higher costs and Oria stayed small at 8%.

Financial results for Q4 2025 reflected this shift. Total revenue reached $163 million, with clinical revenue jumping 32% as behavioural revenue dropped by 17%. The company met its 2025 targets and exceeded guidance, ending the period with 130,000 clinical subscribers. It now expects that number to hit 200,000 by the end of Q1 2026, doubling year-over-year growth. Management has repositioned WeightWatchers for the GLP-1 era, blending clinical care, behavioural support, and digital tools. Early efficacy results have been strong, and the company is expanding its offerings. A rebuilt leadership team is also pushing ahead with technology upgrades to support long-term growth. Looking forward, WeightWatchers anticipates steady subscriber growth in 2026, though demand may dip after the peak season. Revenue for 2026 is forecasted between $620 million and $635 million, with adjusted EBITDA expected in the range of $105 million to $115 million.

The shift to GLP-1-based programmes has reshaped WeightWatchers' business, driving revenue and subscriber gains. With debt sharply reduced and a clearer focus on clinical services, the company aims to sustain growth in a changing weight management market. Analysts will watch whether its expanded offerings can maintain momentum beyond the initial surge.